You are leaving Medscape Education
Cancel Continue
News & Perspective
Drugs & Diseases
CME & Education
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Business of Medicine
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Interprofessional
Shared Decision Making
Nurses
Pharmacists
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Sunday, May 19, 2024
      News & Perspective Drugs & Diseases CME & Education Video Decision Point
      Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
       
       

      CME / CE

      Fine-Tuning the Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction

      • Authors: John Teerlink, MD; G. Michael Felker, MD, MHS; Robert Mentz, MD; Alanna Morris, MD, MSc
      • CME / CE Released: 11/9/2022
      • THIS ACTIVITY HAS EXPIRED FOR CREDIT
      • Valid for credit through: 11/9/2023, 11:59 PM EST
      Start Activity

      Target Audience and Goal Statement

      Healthcare professionals managing patients with heart failure

      1. Recognize the need for optimization of guideline-directed medical therapy (GDMT) as well as novel treatment approaches to reduce the risk of adverse heart failure (HF)-related outcomes in patients with worsening heart failure (WHF) and reduced ejection fraction (EF)

      2. Identify the roles for vericiguat and omecamtiv mecarbil in the treatment of patients with heart failure with reduced ejection fraction (HFrEF)

      3. Identify patients with WHF, optimize GDMT, and tailor treatment with new and emerging agents based on the phenotype of the HFrEF patient

      Learning Objectives

      Upon completion of this activity, participants will be able to:

      • Indicate the outcomes of, and challenges in, the management of patients with HFrEF after a recent worsening heart failure (WHF) event
      • Interpret clinical trial evidence for vericiguat and omecamtiv mecarbil in patients with HFrEF
      • Describe best practices for managing patients with HFrEF with recent WHF

      Disclosures

      Disclosure

      It is the policy of the Heart Failure Society of America (HFSA) to ensure balance, content independent of industry influence, objectivity and scientific rigor in all continuing education (CE) activities, free from the appearance of or actual conflicts of interest (COI).

      Chair

      • John Teerlink, MD

        Professor of Medicine
        University of California, San Francisco School of Medicine
        Director of Heart Failure
        San Francisco Veterans Affairs Medical Center
        San Francisco, California

        Disclosures

        John Teerlink, MD, has the following relevant financial relationships:
        Consultant: 3ive Labs; Abbott Laboratories; Amgen; AstraZeneca; Bayer AG; Boehringer Ingelheim; Bristol Myers Squibb; Cytokinetics; Medtronic; Merck; Novartis; Verily; ViCardia; Windtree Therapeutics
        Contracted Research: Abbott; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cardurion; Cytokinetics; EBR Systems; Medtronic; Novartis; ViCardia; Windtree Therapeutics

      Faculty

      • G. Michael Felker, MD, MHS

        Professor of Medicine
        Vice-Chief for Clinical Research, Duke Cardiology
        Duke University School of Medicine
        Durham, North Carolina

        Disclosures

        G. Michael Felker, MD, MHS, has the following relevant financial relationships:
        Consultant: Abbott Laboratories; American Regent; Arena Pharmaceuticals; Bristol Myers Squibb; Cytokinetics; GlaxoSmithKline; LivaNova; Medtronic; Novartis; Reprieve Cardiovascular; Rocket Pharmaceuticals; Sequana Medical
        Research Support: Amgen; Bayer AG; CSL Behring; Merck

      • Robert Mentz, MD

        Associate Professor of Medicine
        Associate Professor in Population Health Sciences
        Duke University School of Medicine
        Durham, North Carolina

        Disclosures

        Robert Mentz, MD, has the following relevant financial relationships:
        Consultant: Abbott Laboratories; Bayer AG; Boehringer Ingelheim; Cytokinetics; Merck; Novartis
        Research Support: American Regent

      • Alanna Morris, MD, MSc

        Associate Professor of Medicine
        Director of Heart Failure Research
        Emory Clinical Cardiovascular Research Institute
        Atlanta, Georgia

        Disclosures

        Alanna Morris, MD, MSc, has the following relevant financial relationships:
        Research Grants: NHLBI; AHRQ; AHA; Woodruff Foundation; Association of Black Cardiologists
        Consultant: Acorai; BI Lilly; Cytokinetics; Edwards Lifesciences; Ionis, Merck
        Ownership Interest: Gilead Pharmaceuticals

      Voxmedia

      • John Kocsis, PhD

        President

        Disclosures

        John Kocsis, PhD, has no relevant financial relationships.

      Accreditation Statements

      HFSA

      Interprofessional Continuing Education

      In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

        For Physicians

      • The Heart Failure Society of America designates this enduring material activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.

        Contact This Provider

        For Nurses

      • This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America.  This activity is approved for a maximum 1.50 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity. 

        Contact This Provider

        For Pharmacists

      • The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.50 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): JA4008267-0000-22-017-H04-P. 

        Contact This Provider

      For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

      Instructions for Participation and Credit

      There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

      This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 80% on the post-test.

      Follow these steps to earn CME/CE credit*:

      1. Read the target audience, learning objectives, and author disclosures.
      2. Study the educational content online or printed out.
      3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

      You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

      *The credit that you receive is based on your user profile.

      From Medscape Education Cardiology
      CME / CE

      Fine-Tuning the Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction

      Authors: John Teerlink, MD; G. Michael Felker, MD, MHS; Robert Mentz, MD; Alanna Morris, MD, MScFaculty and Disclosures
      THIS ACTIVITY HAS EXPIRED FOR CREDIT

      CME / CE Released: 11/9/2022

      Valid for credit through: 11/9/2023, 11:59 PM EST

      processing....

      Assessment Survey

      Before you begin, please take this brief survey. 

      Page 1 of 2
      CME / CE Information
      • Print
      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Manage Preferences Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.